VAUGHAN, Ontario / Apr 17, 2023 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, will release its first-quarter 2023 financial results on Wednesday, May 3, 2023. Bausch + Lomb will host a conference call and live web cast at 8:00 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the call.
Conference Call Details
Date: | Wednesday, May 3, 2023 | |||||
Time: | 8:00 a.m. ET | |||||
Webcast: | ||||||
Participant Event Dial-in: | +1 (888) 506-0062 (North America) +1 (973) 528-0011 (International) | |||||
Participant Access Code: | 937525 | |||||
Replay Dial-in: | +1 (877) 481-4010 (North America) +1 (919) 882-2331 (International) | |||||
Replay Passcode: | 47444 (replay available until May 17, 2023) |
About Bausch + Lomb
Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from the moment of birth through every phase of life. Its comprehensive portfolio of more than 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,000 employees and a presence in nearly 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario with corporate offices in Bridgewater, New Jersey. For more information, visit www.bausch.com and connect with us on Twitter, LinkedIn, Facebook and Instagram.
© 2023 Bausch & Lomb Incorporated or its affiliates.
| Last Trade: | US$10.84 |
| Daily Change: | -0.53 -4.66 |
| Daily Volume: | 1,192,049 |
| Market Cap: | US$3.820B |
April 30, 2025 February 19, 2025 January 13, 2025 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
